A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF(V600E) colorectal tumors
Author: Ruiz-Saenz, Ana; Atreya, Chloe E.; Wang, Changjun; Pan, Bo; Dreyer, Courtney A.; Brunen, Diede; Prahallad, Anirudh; Munoz, Denise P.; Ramms, Dana J.; Burghi, Valeria; Spassov, Danislav S.; Fewings, Eleanor; Hwang, Yeonjoo C.; Cowdrey, Cynthia; Moelders, Christina; Schwarzer, Cecilia; Wolf, Denise M.; Hann, Byron; VandenBerg, Scott R.; Shokat, Kevan; Moasser, Mark M.; Bernards, Rene; Gutkind, J. Silvio; van 't Veer, Laura J.; Coppe, Jean-Philippe
EZH2 inhibition remodels the inflammatory senescence-associated secretory phenotype to potentiate pancreatic cancer immune surveillance
Author: Chibaya, Loretah; Murphy, Katherine C. C.; DeMarco, Kelly D. D.; Gopalan, Sneha; Liu, Haibo; Parikh, Chaitanya N. N.; Lopez-Diaz, Yvette; Faulkner, Melissa; Li, Junhui; Morris, John P. P.; Ho, Yu-jui; Chana, Sachliv K. K.; Simon, Janelle; Luan, Wei; Kulick, Amanda; de Stanchina, Elisa; Simin, Karl; Zhu, Lihua Julie; Fazzio, Thomas G. G.; Lowe, Scott W. W.; Ruscetti, Marcus
Disrupting the phase separation of KAT8-IRF1 diminishes PD-L1 expression and promotes antitumor immunity
Nature Cancer aims to publish the most significant advances across the full spectrum of cancer research in the life, physical, applied and social sciences, spanning basic preclinical, translational and clinical work. The journal’s broad scope covers all cancer research offering new insights into cancer biology, genetics and genomics, new approaches for the development and delivery of diagnostics and therapies, and new ways of understanding the global societal impact of cancer, thus ensuring that the work published reaches the widest possible audience.